PHGE Earnings

PHGE reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 0.00 against an estimate of , resulting in a 0% surprise. The EPS was -0.29, surpassing the expected -0.32 by 9.38%. The stock experienced a -1.88% price change on the earnings day and a -17.5% change over the next five days, reflecting market reactions to the results.

Following PHGE's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -1.88% on the day of the release. Over the subsequent five days, it saw a -17.5% change. Historically, PHGE's stock price tends to shift by an average of 5.4% in the 10 days leading up to earnings and -10.15% in the 10 days following, providing insight into potential market.

For , analysts estimate PHGE's annual revenue to reach undefined, while the EPS is projected at -6.08. These estimates reflect recent revisions, with revenue estimates revised downward by -5.32% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PHGE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised downward by -5.32%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PHGE's stock price typically moves by 5.4% in the 10 days before its earnings and -10.15% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -6.08 and revenue of undefined.

The earnings call highlighted significant financial challenges, including a substantial net loss and a declining cash balance. Despite some positive developments, such as potential DHA support and FDA feedback, the financial health concerns and lack of clear guidance on critical issues, like the nebulizer hold, overshadowed these positives. The Q&A revealed management's vague responses, especially regarding the Phase III study for BX004, contributing to uncertainty. These factors, combined with the operational reductions and financial risks, suggest a likely negative impact on the stock price.